Reynoso-Roa Africa Samantha, Gutiérrez-Rubio Susan Andrea, Magallón-Gastélum Ezequiel, García-Iglesias Trinidad, Suárez-Rico Daniel Osmar, García-Cobián Teresa Arcelia
Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Calle Sierra Mojada 950, Independencia Oriente, Guadalajara 44340, Mexico.
Life (Basel). 2025 Apr 2;15(4):585. doi: 10.3390/life15040585.
Resistin is an adipokine produced in adipose tissue with pro-inflammatory properties, whose elevation has been associated with insulin resistance and diabetes. Over the past years, significant research has explored the pathophysiological mechanisms involving resistin, utilizing various in vitro and in vivo models. Additionally, numerous clinical studies have aimed to establish a correlation between resistin and the development and progression of macrovascular and microvascular complications in type 2 diabetes. This narrative review summarizes in vitro, in vivo, and human studies published in English since the discovery of resistin in 2001 to the present, examining the role of this adipokine in the pathophysiology of macrovascular and microvascular complications in in vivo and in vitro T2D models, as well as the clinical evidence supporting its use as a biochemical marker in patients with these conditions. The results exhibit considerable heterogeneity and appear to be dependent on the experimental model or population studied. While experimental evidence supports resistin's involvement at the cellular and molecular levels in the pathogenesis of these complications, current clinical evidence remains insufficient to justify its use as a biochemical marker for either diagnosis or prognosis. Therefore, further well-designed studies are required to elucidate resistin's potential role in the clinical setting.
抵抗素是一种在脂肪组织中产生的具有促炎特性的脂肪因子，其水平升高与胰岛素抵抗和糖尿病有关。在过去几年中，大量研究利用各种体外和体内模型探索了涉及抵抗素的病理生理机制。此外，许多临床研究旨在建立抵抗素与2型糖尿病大血管和微血管并发症的发生及进展之间的关联。这篇叙述性综述总结了自2001年发现抵抗素至今以英文发表的体外、体内和人体研究，探讨了这种脂肪因子在体内和体外2型糖尿病模型中大血管和微血管并发症病理生理过程中的作用，以及支持将其用作这些疾病患者生化标志物的临床证据。结果显示出相当大的异质性，且似乎取决于所研究的实验模型或人群。虽然实验证据支持抵抗素在这些并发症发病机制的细胞和分子水平上发挥作用，但目前的临床证据仍不足以证明将其用作诊断或预后的生化标志物是合理的。因此，需要进一步设计良好的研究来阐明抵抗素在临床环境中的潜在作用。
